ClinicalTrials.gg
Drug

Liposomal Bupivacaine clinical trials

A product of Bupivacaine; its studies count on that page too.

studies test it
298
open now
49
in phase 3
49
first study started
2011

How each study uses Liposomal Bupivacaine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Liposomal Bupivacaine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Oct 2011 · EXPAREL · NDA 022496 (FDA, Drugs@FDA)
European Union
16 Nov 2020 · Exparel liposomal · EMEA/H/C/004586 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Exparel
181
Liposomal bupivacaine
155
bupivacaine liposome injectable suspension
31
Liposomal bupivacaine plus bupivacaine
7
Liposomal bupivacaine (LB)
6

Development codes

SKY0402
1

Studies by the year they started

296 studies that test it; most in 2019 (40); 1 more planned to start later

Studies that test Liposomal Bupivacaine, by start year
YearStudies
20112
201210
201313
201429
201524
201620
201718
201827
201940
202017
202123
202213
202311
202421
20258
202620

By phase

A phase 1/2 study counts in both.

Early Phase 1
7
Phase 1
19
Phase 2
31
Phase 3
49
Phase 4
165
No phase
37

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 38 · Other 260

Pacira Pharmaceuticals, Inc (35) · Mayo Clinic (11) · University of Minnesota (9) · Wake Forest University Health Sciences (9) · Beijing Tiantan Hospital (6) · St. Luke's Hospital, Pennsylvania (4) · The Cleveland Clinic (4) · Indiana University (4)

Often tested with

Tested in the same studies.

Ropivacaine (10) · Dexamethasone (7) · Epinephrine (6) · Hydromorphone (3) · Methylprednisolone (2) · Fentanyl (1) · Therapeutic Procedure (1) · Complementary or Alternative Medical Procedure (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Liposomal Bupivacaine is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 24, 5 in phase 3

Studies that test Liposomal Bupivacaine, phase 3 first.

Studies

Open first, then newest update. How each study uses Liposomal Bupivacaine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 298

See all 298 studies that test Liposomal Bupivacaine →

Given beside what is tested · 11 — Liposomal Bupivacaine is usual care or a partner of the new treatment
As the comparator · 10 — what is tested is compared with Liposomal Bupivacaine

What changed recently

From the registry's own updates since Oct 17, 2026.